Issue 7, 2018

Synthesis of a novel HER2 targeted aza-BODIPY–antibody conjugate: synthesis, photophysical characterisation and in vitro evaluation

Abstract

We herein report the synthesis and analysis of a novel aza-BODIPY–antibody conjugate, formed by controlled and regioselective bioconjugation methodology. Employing the clinically relevant antibody, which targets HER2 positive cancers, represents an excellent example of an antibody targeting strategy for this class of near-IR emitting fluorophore. The NIR fluorescence and binding properties were validated through in vitro studies using live cell confocal imaging.

Graphical abstract: Synthesis of a novel HER2 targeted aza-BODIPY–antibody conjugate: synthesis, photophysical characterisation and in vitro evaluation

Supplementary files

Article information

Article type
Paper
Submitted
30 Nov 2017
Accepted
16 Jan 2018
First published
16 Jan 2018
This article is Open Access
Creative Commons BY license

Org. Biomol. Chem., 2018,16, 1144-1149

Synthesis of a novel HER2 targeted aza-BODIPY–antibody conjugate: synthesis, photophysical characterisation and in vitro evaluation

Miffy. H. Y. Cheng, A. Maruani, H. Savoie, V. Chudasama and Ross. W. Boyle, Org. Biomol. Chem., 2018, 16, 1144 DOI: 10.1039/C7OB02957H

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements